ISMPO Guidelines for Diagnosis and Management of Early Breast Cancer

Abstract

The management of breast cancer has become increasingly complex and multidisciplinary in the recent past. Further, there are unique constraints and opportunities for cancer care delivery in India, including socioeconomic, geographic, and other disparities. Therefore, the Indian Society of Medical and Paediatric Oncology convened a panel of experts to create evidence and context-based guidelines for the management of early breast cancer.

Keywords

early breast cancer - guidelines - ISMPO - medical oncology

Authors' Contributions

S.A., A.S., R.S. contributed in Concept, Design and Intellectual content whereas S.G., P.K., S.A. reviewed the manuscript. All authors were involved in Literature search, Clinical studies, Data analysis, Manuscript preparation and Editing.

Publication History

Article published online:
18 July 2024

• References

• 1 Kulothungan V, Sathishkumar K, Leburu S. et al. Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC Cancer 2022; 22 (01) 527
• 2 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6: 1063-1075
• 3 Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis. Br J Cancer 2011; 105 (05) 723-730
• 4 Mittal A, Deo SVS, Gogia A. et al. Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a North Indian tertiary care center. Ann Surg Oncol 2022; 29 (02) 1423-1432
• 5 Yanes T, Young MA, Meiser B, James PA. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field. Breast Cancer Res 2020; 22 (01) 21
• 6 Nagrani R, Mhatre S, Rajaraman P. et al. Central obesity increases risk of breast cancer irrespective of menopausal and hormonal receptor status in women of South Asian Ethnicity. Eur J Cancer 2016; 66: 153-161
• 7 Lammert J, Grill S, Kiechle M. Modifiable lifestyle factors: opportunities for (hereditary) breast cancer prevention - a narrative review. Breast Care (Basel) 2018; 13 (02) 109-114
• 8 Fortner RT, Sisti J, Chai B. et al. Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. Breast Cancer Res 2019; 21 (01) 40
• 9 Thangjam S, Laishram RS, Debnath K. Breast carcinoma in young females below the age of 40 years: a histopathological perspective. South Asian J Cancer 2014; 3 (02) 97-100
• 10 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
• 11 Mittra I, Mishra GA, Dikshit RP. et al. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ 2021; 372: n256
• 12 Lad S, Bajaj P, Chandra M. et al. Standard reporting formats & basic imaging protocols for breast imaging ICRI sub-specialty group for breast imaging standard reporting formats & basic imaging protocols for mammogram, breast ultrasound & breast MRI. Accessed April 11, 2024 at: https://icri.iria.org.in/about-icri/radiology-imaging-guidelines/breast-imaging-reporting-formats
• 13 Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 2018; 15 (3 Pt A): 408-414
• 14 Hortobagyi GN, Connolly JL, D'Orsi CJ. et al. Breast. In: Amin MB, Edge S, Greene F. et al, eds. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed.. New York, NY: Springer; 2017: 589-636 . Last updated March 13, 2018. Accessed May 14, 2018 at: https://pubmed.ncbi.nlm.nih.gov/31928404/
• 15 Allison KH, Hammond MEH, Dowsett M. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38 (12) 1346-1366
• 16 Nielsen TO, Leung SCY, Rimm DL. et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2021; 113 (07) 808-819
• 17 Coates AS, Winer EP, Goldhirsch A. et al; Panel Members. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26 (08) 1533-1546
• 18 Paik S, Tang G, Shak S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24 (23) 3726-3734
• 19 Sparano J, Gray RJ, Wood WC. et al. TAILORx: Phase III trial of chemo endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2- negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score [Abstract]. J Clin Oncol 2018 ;36(18_suppl)
• 20 Cardoso F, van't Veer LJ, Bogaerts J. et al; MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375 (08) 717-729
• 21 Sestak I, Buus R, Cuzick J. et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018; 4 (04) 545-553
• 22 Filipits M, Rudas M, Jakesz R. et al; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17 (18) 6012-6020
• 23 Sgroi DC, Sestak I, Cuzick J. et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14 (11) 1067-1076
• 24 Bakre MM, Ramkumar C, Attuluri AK. et al. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Med 2019; 8 (04) 1755-1764
• 25 Tomlinson-Hansen S, Khan M, Cassaro S. Breast ductal carcinoma in situ. In: StatPearls. StatPearls Publishing; Treasure Island (FL): ; 2023 Accesed January 5, 2024 at: https://europepmc.org/article/nbk/nbk567766
• 26 Morrow M, Van Zee KJ, Solin LJ. et al. Society of Surgical Oncology- American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol 2016; 34 (33) 4040-4046
• 27 Seijen M, Lips EH, Thompson AM. et al. PRECISION Team. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer 2019; 121 (04) 285-292
• 28 Fisher B, Anderson S, Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16) 1233-1241
• 29 Moran MS, Schnitt SJ, Giuliano AE. et al; Society of Surgical Oncology, American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32 (14) 1507-1515
• 30 Losken A, Dugal CS, Styblo TM, Carlson GW. A meta-analysis comparing breast conservation therapy alone to the oncoplastic technique. Ann Plast Surg 2014; 72 (02) 145-149
• 31 Rosenkranz KM, Ballman K, McCall L. et al. Cosmetic outcomes following breast-conservation surgery and radiation for multiple ipsilateral breast cancer: data from the Alliance Z11102 Study. Ann Surg Oncol 2020; 27 (12) 4650-4661
• 32 Fayanju OM, Stoll CR, Fowler S, Colditz GA, Margenthaler JA. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014; 260 (06) 1000-1010
• 33 Medina-Franco H, Vasconez LO, Fix RJ. et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002; 235 (06) 814-819
• 34 Duarte C, Bastidas F, de los Reyes A. et al. Randomized controlled clinical trial comparing radioguided occult lesion localization with wire-guided lesion localization to evaluate their efficacy and accuracy in the localization of nonpalpable breast lesions. Surgery 2016; 159 (04) 1140-1145
• 35 Parmar V, Hawaldar R, Nair NS. et al. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast 2013; 22 (06) 1081-1086
• 36 Parmar V, Nair NS, Vanmali V. et al. Sentinel node biopsy Versus low axillary sampling in predicting nodal status of postchemotherapy axilla in women with breast cancer. JCO Glob Oncol 2020; 6: 1546-1553
• 37 Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed MW. Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 2017; 1 (01) CD004561
• 38 Giuliano AE, Hunt KK, Ballman KV. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305 (06) 569-575
• 39 Kuehn T, Bauerfeind I, Fehm T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14 (07) 609-618
• 40 Boughey JC, Suman VJ, Mittendorf EA. et al; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310 (14) 1455-1461
• 41 Boileau JF, Poirier B, Basik M. et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; 33 (03) 258-264
• 42 Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel) 2021; 13 (07) 13
• 43 Vinh-Hung V, Verschraegen C, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004; 96 (02) 115-121
• 44 Darby S, McGale P, Correa C. et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804) 1707-1716
• 45 Bartelink H, Maingon P, Poortmans P. et al; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16 (01) 47-56
• 46 Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol 2009; 90 (01) 1-13
• 47 Vicini FA, Cecchini RS, White JR. et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019; 394 (10215): 2155-2164
• 48 Coles CE, Griffin CL, Kirby AM. et al; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017; 390 (10099): 1048-1060
• 49 Whelan TJ, Julian JA, Berrang TS. et al; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019; 394 (10215): 2165-2172
• 50 Monticciolo DL, Malak SF, Friedewald SM. et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and Society of Breast Imaging. J Am Coll Radiol 2021; 18 (09) 1280-1288
• 51 Ott OJ, Strnad V, Hildebrandt G. et al; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external beam whole breast irradiation: Early toxicity and patient compliance. Radiother Oncol 2016; 120 (01) 119-123
• 52 Veronesi U, Orecchia R, Maisonneuve P. et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2013; 14 (13) 1269-1277
• 53 Polgár C, Van Limbergen E, Pötter R. et al; GEC-ESTRO Breast Cancer Working Group. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010; 94 (03) 264-273
• 54 McGale P, Taylor C, Correa C. et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383 (9935) 2127-2135
• 55 Tabár L, Dean PB, Chen TH. et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer 2019; 125 (04) 515-523
• 56 Cosar R, Uzal C, Tokatli F. et al. Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: is there a role for radiation therapy?. Radiat Oncol 2011; 6 (01) 28
• 57 Zhang J, Wang C. Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer. Sci Rep 2016; 6: 26304
• 58 Whelan TJ, Olivotto IA, Parulekar WR. et al; MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373 (04) 307-316
• 59 Poortmans PM, Collette S, Kirkove C. et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373 (04) 317-327
• 60 Haviland JS, Owen JR, Dewar JA. et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14 (11) 1086-1094
• 61 Smith BD, Bellon JR, Blitzblau R. et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018; 8 (03) 145-152
• 62 Murray Brunt A, Haviland JS, Wheatley DA. et al; FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395 (10237): 1613-1626
• 63 Francis PA, Pagani O, Fleming GF. et al; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379 (02) 122-137
• 64 Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows. J Clin Oncol 2019; 37 (11) 862-866
• 65 Dowsett M, Cuzick J, Ingle J. et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28 (03) 509-518
• 66 Coombes RC, Kilburn LS, Snowdon CF. et al; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369 (9561) 559-570
• 67 Morden JP, Alvarez I, Bertelli G. et al. Long-term follow-up of the Intergroup Exemestane Study. J Clin Oncol 2017; 35 (22) 2507-2514
• 68 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386 (10001): 1341-1352
• 69 Johnston SRD, Harbeck N, Hegg R. et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020; 38 (34) 3987-3998
• 70 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13 (01) 25-32
• 71 van Ramshorst MS, van der Voort A, van Werkhoven ED. et al; Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19 (12) 1630-1640
• 72 Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2011; 22 (01) 17-23
• 73 Curigliano G, Viale G, Bagnardi V. et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27 (34) 5693-5699
• 74 Bahl A, Singh R, Wadhwa J. et al. Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. South Asian J Cancer 2018; 7 (02) 102-105
• 75 Tolaney SM, Barry WT, Dang CT. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372 (02) 134-141
• 76 Tolaney SM, Tayob N, Dang C. et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol 2021; 39 (21) 2375-2385
• 77 Manuprasad A, Shenoy PK, Jones J, Vinin NV, Dharmarajan A, Muttath G. Short-course adjuvant trastuzumab in breast cancer: Experience from a tertiary cancer center in rural India. Cancer Res Stat Treat 2020; 3: 69-73
• 78 Gulia S, Kannan S, Badwe R, Gupta S. Evaluation of 1-year vs shorter durations of adjuvant trastuzumab among patients with early breast cancer: an individual participant data and trial-level meta-analysis. JAMA Netw Open 2020; 3 (08) e2011777
• 79 von Minckwitz G, Huang CS, Mano MS. et al; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380 (07) 617-628
• 80 Loibl S, Jassem J. Sonnenblick, et al. Adjuvant pertuzumab and trastuzumab in patients with HER2 positive breast cancer in APHINITY: 8.4 years follow up. Ann Oncol 2022; 33 (09) 986-987 . Accessed August 1, 2022 at: https://www.annalsofoncology.org/article/S0923-7534(22)01738-0/fulltext
• 81 Citron ML, Berry DA, Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21 (08) 1431-1439
• 82 Blum JL, Flynn PJ, Yothers G. et al. Anthracyclines in early breast cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017; 35 (23) 2647-2655
• 83 Pathak N, Sharma A, Elavarasi A. et al. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. Breast 2022; 64: 7-18
• 84 Gupta S, Nair NS, Hawaldar R. et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6–10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 suppl):Abstract nr GS5–01
• 85 Hahnen E, Lederer B, Hauke J. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary Analysis of the GeparSixto randomized clinical trial. JAMA Oncol 2017; 3 (10) 1378-1385
• 86 Masuda N, Lee SJ, Ohtani S. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376 (22) 2147-2159
• 87 Schmid P, Cortes J, Pusztai L. et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382 (09) 810-821
• 88 Tutt ANJ, Garber JE, Kaufman B. et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021; 384 (25) 2394-2405
• 89 Parikh PM, Bhattacharyya GS, Biswas G. et al. Practical consensus recommendations for optimizing risk versus benefit of chemotherapy in patients with HR positive Her2 negative early breast cancer in India. South Asian J Cancer 2021; 10 (04) 213-219
• 90 Banerjee J, Behal P, Satapathy S. et al. Implementing and validating a care protocol for older adults with cancer in resource limited settings with a newly developed screening tool. J Geriatr Oncol 2021; 12 (01) 139-145
• 91 Brufsky A, Bundred N, Coleman R. et al; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008; 13 (05) 503-514
• 92 Gnant MF, Mlineritsch B, Luschin-Ebengreuth G. et al; Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25 (07) 820-828
• 93 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386 (10001): 1353-1361
• 94 Gnant M, Pfeiler G, Steger GG. et al; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (03) 339-351
• 95 Coleman R, Finkelstein DM, Barrios C. et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21 (01) 60-72
• 96 Bajpai J, Shylasree T. Pregnancy-associated breast cancer: controversies and consensus!. Oncobiology and Targets 2016; 3: 6
• 97 Langer A, Mohallem M, Berment H. et al. Breast lumps in pregnant women. Diagn Interv Imaging 2015; 96 (10) 1077-1087
• 98 Bajpai J, Simha V, Shylasree TS. et al. Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India. Breast 2021; 56: 88-95
• 99 Amant F, Lefrère H, Borges VF. et al. The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncol 2021; 22 (06) 753-754
• 100 Loibl S, Schmidt A, Gentilini O. et al. Breast cancer diagnosed during pregnancy adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol 2015; 1 (08) 1145-1153
• 101 Paris I, Di Giorgio D, Carbognin L. et al. Pregnancy-associated breast cancer: a multidisciplinary approach. Clin Breast Cancer 2021; 21 (01) e120-e127
• 102 Vashi R, Hooley R, Butler R, Geisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. AJR Am J Roentgenol 2013; 200 (02) 321-328
• 103 Partridge AH, Niman SM, Ruggeri M. et al; International Breast Cancer Study Group, POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med 2023; 388 (18) 1645-1656
• 104 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68 (01) 7-30
• 105 Noone AM, Howlader N, Krapcho M. et al, Eds. SEER Cancer Statistics Review, 1975–2015. National Cancer Institute; 2018. . Accessed December 4, 2018 at: https://seer.cancer.gov/csr/1975_2015
• 106 Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115 (02) 429-430
• 107 Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat 2004; 83 (01) 77-86
• 108 Sathwara J, Bobdey SBG. Breast cancer survival studies in India: a review. Int J Res Med Sci 2017; 4 (08) 3102-3108 . Accessed 2023 October 29, 2023 at: https://www.msjonline.org/index.php/ijrms/article/view/1084
• 109 Mustian KM, Alfano CM, Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer- related fatigue: a meta-analysis. JAMA Oncol 2017; 3 (07) 961-968
• 110 Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20 (04) 1128-1143
• 111 Holmberg L, Iversen OE, Rudenstam CM. et al; HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100 (07) 475-482